NAFLD1
MCID: FTT008
MIFTS: 60

Fatty Liver Disease, Nonalcoholic 1 (NAFLD1)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 56 29 6
Hepatic Steatosis 73 29 6
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 56 13
Nafld1 56 73
Non-Alcoholic Fatty Liver Disease 1 73
Steatohepatitis 71
Fatty Liver 71

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

31
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 56 613282
MeSH 43 D005234
SNOMED-CT via HPO 68 197321007 442191002
UMLS 71 C0015695 C2711227

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 56 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipodystrophy, congenital generalized, type 1 and familial partial lipodystrophy. An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Metabolism and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Entecavir and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and adipocyte, and related phenotypes are hepatic steatosis and homeostasis/metabolism

UniProtKB/Swiss-Prot : 73 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Fatty Liver Disease, Nonalcoholic 1 family:

Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 343, show less)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, congenital generalized, type 1 31.5 LEP INS ADIPOQ
2 familial partial lipodystrophy 31.4 RETN LEP INS ADIPOQ
3 abetalipoproteinemia 31.3 PNPLA3 MTTP LEP HADHA
4 acquired generalized lipodystrophy 31.3 RETN LEP ADIPOQ
5 lipodystrophy, familial partial, type 2 31.1 PPARA LEP INS ADIPOQ
6 portal hypertension 30.7 PNPLA3 INS GPT
7 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.4 LEP INS ADIPOQ
8 alcohol use disorder 30.4 SLC17A5 GPT GGT1
9 kwashiorkor 30.4 SLC17A5 INS GPT
10 choline deficiency disease 30.4 PPARA INS GPT
11 cholestasis 30.3 SLC17A5 HADHA GPT GGT1
12 alcoholic hepatitis 30.2 SLC17A5 PNPLA3 GPT GGT1
13 viral hepatitis 30.2 SLC17A5 PNPLA3 INS GPT GGT1
14 bilirubin metabolic disorder 30.2 SLC17A5 GPT GGT1
15 pancreatitis 30.1 SLC17A5 INS GGT1
16 hyperglycemia 30.0 RETN LEP INS ADIPOQ
17 platelet glycoprotein iv deficiency 30.0 PPARA INS
18 esophageal varix 30.0 GPT GGT1
19 reye syndrome 29.9 HADHA GPT
20 glucose intolerance 29.8 RETN LEP INS GPT ADIPOQ
21 gallbladder disease 29.8 INS GPT GGT1
22 placenta disease 29.7 INS HADHA ADIPOQ
23 acute liver failure 29.6 SLC17A5 GPT
24 acute pancreatitis 29.6 RETN INS GPT
25 non-alcoholic steatohepatitis 29.6 PPARA PNPLA3 MTTP INS GPT GGT1
26 fetal macrosomia 29.6 LEP INS
27 alcohol dependence 29.5 SLC17A5 LEP GPT GGT1
28 hyperinsulinism 29.5 RETN PPARA LEP INS ADIPOQ
29 polycystic ovary syndrome 29.4 RETN LEP INS ADIPOQ
30 hypothalamic obesity 29.4 RETN LEP INS
31 hyperuricemia 29.4 LEP INS GPT GGT1
32 acromegaly 29.4 LEP INS ADIPOQ
33 acanthosis nigricans 29.3 PRMT7 LEP INS ADIPOQ
34 familial hypercholesterolemia 29.2 MTTP INS GPT ADIPOQ
35 atherosclerosis susceptibility 29.2 RETN PPARA LEP INS ADIPOQ
36 fatty liver disease 29.2 SLC17A5 RETN PPARA PNPLA3 MTTP LEP
37 vascular disease 29.1 RETN LEP INS ADIPOQ
38 nutritional deficiency disease 29.1 RETN LEP ADIPOQ
39 liver cirrhosis 29.0 SLC17A5 RETN LEP GPT GGT1 ADIPOQ
40 cholelithiasis 29.0 LEP INS GPT GGT1
41 gestational diabetes 29.0 RETN LEP INS ADIPOQ
42 hypothyroidism 28.9 RETN LEP INS GPT ADIPOQ
43 arteries, anomalies of 28.9 LEP INS ADIPOQ
44 hyperthyroidism 28.8 RETN LEP INS GPT
45 chronic kidney disease 28.8 RETN LEP INS FABP1 ADIPOQ
46 leptin deficiency or dysfunction 28.8 RETN PPARA LEP INS ADIPOQ
47 sleep apnea 28.7 RETN LEP INS GPT ADIPOQ
48 lipid metabolism disorder 28.6 RETN PPARA MTTP LEP INS GGT1
49 prediabetes syndrome 28.4 PPARA LEP INS GPT ADIPOQ
50 apnea, obstructive sleep 28.4 RETN LEP INS GPT ADIPOQ
51 kidney disease 28.4 RETN LEP INS FABP1 ADIPOQ
52 overnutrition 28.4 RETN PPARA LEP INS GPT ADIPOQ
53 non-alcoholic fatty liver disease 28.3 RETN PPARA PNPLA3 NAFLD1 MTTP LEP
54 diabetes mellitus 28.1 RETN PPARA LEP INS GPT GGT1
55 liver disease 28.0 SLC17A5 RETN PPARA PNPLA3 LEP INS
56 familial hyperlipidemia 27.8 PRMT7 PPARA MTTP LEP INS GPT
57 lipid storage disease 27.7 PPARA PNPLA3 LEP INS GPT GGT1
58 hypertension, essential 27.3 RETN PPARA LEP INS GPT GGT1
59 cardiovascular system disease 27.3 RETN PPARA MTTP LEP INS GGT1
60 diabetes mellitus, noninsulin-dependent 26.5 SLC17A5 RETN PRMT7 PPARA PNPLA3 MTTP
61 body mass index quantitative trait locus 11 26.4 SLC17A5 RETN PRMT7 PPARA PNPLA3 MTTP
62 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.4
63 congenital generalized lipodystrophy 11.6
64 hypobetalipoproteinemia, familial, 1 11.6
65 citrullinemia, type ii, adult-onset 11.6
66 lipodystrophy, congenital generalized, type 2 11.4
67 3-methylglutaconic aciduria, type v 11.4
68 lipodystrophy, congenital generalized, type 3 11.4
69 lipodystrophy, familial partial, type 6 11.4
70 visceral steatosis 11.4
71 chylomicron retention disease 11.3
72 adrenomyodystrophy 11.3
73 mitochondrial trifunctional protein deficiency 11.3
74 neutral lipid storage disease with myopathy 11.3
75 lipodystrophy, congenital generalized, type 4 11.3
76 lipodystrophy, familial partial, type 5 11.3
77 muscular dystrophy, limb-girdle, autosomal recessive 18 11.3
78 combined oxidative phosphorylation deficiency 16 11.3
79 combined oxidative phosphorylation deficiency 21 11.3
80 microcephaly, developmental delay, and brittle hair syndrome 11.3
81 hepatitis c 10.8
82 hepatitis c virus 10.7
83 hypertriglyceridemia, familial 10.7
84 hepatitis b 10.7
85 body mass index quantitative trait locus 1 10.6
86 hypercholesterolemia, familial, 1 10.6
87 fibrosis of extraocular muscles, congenital, 1 10.5
88 hepatocellular carcinoma 10.5
89 hepatitis 10.5
90 body mass index quantitative trait locus 9 10.4
91 body mass index quantitative trait locus 8 10.4
92 body mass index quantitative trait locus 4 10.4
93 body mass index quantitative trait locus 10 10.4
94 body mass index quantitative trait locus 7 10.4
95 body mass index quantitative trait locus 12 10.4
96 body mass index quantitative trait locus 14 10.4
97 body mass index quantitative trait locus 18 10.4
98 body mass index quantitative trait locus 19 10.4
99 body mass index quantitative trait locus 20 10.4
100 hypoglycemia 10.4
101 rapidly involuting congenital hemangioma 10.4
102 paraquat poisoning 10.4 SLC17A5 GPT
103 lactic acidosis 10.3
104 critical illness polyneuropathy 10.3 INS GPT
105 pyridoxine deficiency anemia 10.3 SLC17A5 GPT
106 methotrexate toxicity 10.3 SLC17A5 GPT
107 hemosiderosis 10.3
108 rare hereditary hemochromatosis 10.3
109 overgrowth syndrome 10.3
110 infantile liver failure syndrome 1 10.3 SLC17A5 GPT
111 hepatic tuberculosis 10.3 GPT GGT1
112 cystic fibrosis 10.3
113 proteasome-associated autoinflammatory syndrome 1 10.3
114 ischemia 10.3
115 suppurative cholangitis 10.3 GPT GGT1
116 viral laryngitis 10.2 GPT GGT1
117 colorectal cancer 10.2
118 celiac disease 1 10.2
119 microvascular complications of diabetes 3 10.2
120 microvascular complications of diabetes 4 10.2
121 microvascular complications of diabetes 6 10.2
122 microvascular complications of diabetes 7 10.2
123 diabetes mellitus, insulin-dependent, 20 10.2 INS FABP1
124 rocky mountain spotted fever 10.2 SLC17A5 GPT
125 acute cholangitis 10.2 GPT GGT1
126 analbuminemia 10.2 SLC17A5 GPT
127 bile duct cysts 10.2 GPT GGT1
128 algoneurodystrophy 10.2 INS GGT1
129 immune deficiency disease 10.2
130 insulinoma 10.2
131 hypoxia 10.2
132 monocarboxylate transporter 1 deficiency 10.2 INS GGT1
133 common bile duct disease 10.2 GPT GGT1
134 bleeding disorder, platelet-type, 14 10.2 RETN INS
135 nasopharyngitis 10.2 INS GPT
136 homocysteinemia 10.1
137 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
138 inflammatory bowel disease 10.1
139 short bowel syndrome 10.1
140 rickets 10.1
141 hypogonadism 10.1
142 47,xyy 10.1
143 48,xyyy 10.1
144 cytokine deficiency 10.1
145 genetic obesity 10.1
146 drug allergy 10.1 INS GPT
147 opisthorchiasis 10.1 GPT GGT1
148 pellagra 10.1 INS GPT ADIPOQ
149 hair whorl 10.1
150 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.1
151 aging 10.1
152 helix syndrome 10.1
153 fetal akinesia deformation sequence 2 10.1
154 deficiency anemia 10.1
155 disseminated intravascular coagulation 10.1
156 diarrhea 10.1
157 hemolytic anemia 10.1
158 cryptogenic cirrhosis 10.1
159 encephalopathy 10.1
160 posttransplant acute limbic encephalitis 10.1
161 parenteral nutrition-associated cholestasis 10.1 SLC17A5 GPT GGT1
162 liver benign neoplasm 10.1 PPARA FABP1
163 vein disease 10.1 INS GPT GGT1
164 choledocholithiasis 10.1 SLC17A5 GPT GGT1
165 hepatitis a 10.0 INS GPT GGT1
166 compartment syndrome 10.0 SLC17A5 GPT
167 obstructive jaundice 10.0 SLC17A5 GPT GGT1
168 cholangitis 10.0 SLC17A5 GPT GGT1
169 autoimmune hepatitis 10.0 SLC17A5 GPT GGT1
170 breast cancer 10.0
171 varicose veins 10.0
172 acyl-coa dehydrogenase, medium-chain, deficiency of 10.0
173 visceral steatosis, congenital 10.0
174 hemochromatosis, type 1 10.0
175 ocular motor apraxia 10.0
176 citrullinemia, type ii, neonatal-onset 10.0
177 psoriatic arthritis 10.0
178 carbonic anhydrase va deficiency, hyperammonemia due to 10.0
179 estrogen-receptor positive breast cancer 10.0
180 siderosis 10.0
181 lipoid nephrosis 10.0
182 respiratory failure 10.0
183 hyperandrogenism 10.0
184 hepatic coma 10.0
185 hepatic encephalopathy 10.0
186 psychotic disorder 10.0
187 glycogen storage disease 10.0
188 hepatoblastoma 10.0
189 crohn's disease 10.0
190 hypopituitarism 10.0
191 berardinelli-seip congenital lipodystrophy 10.0
192 metastatic insulinoma 10.0
193 splenomegaly 10.0
194 acyl-coa dehydrogenase deficiency 10.0
195 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 10.0 MTTP HADHA
196 3-hydroxyacyl-coa dehydrogenase deficiency 10.0 MTTP HADHA
197 alcoholic liver cirrhosis 10.0 SLC17A5 PNPLA3 INS GPT
198 idiopathic edema 9.9 PPARA INS ADIPOQ
199 extrahepatic cholestasis 9.9 GPT GGT1
200 hyperlipidemia, familial combined, 3 9.9 PPARA INS ADIPOQ
201 nontuberculous mycobacterial lung disease 9.9 LEP ADIPOQ
202 hypothalamic disease 9.9 LEP INS
203 pica disease 9.9 LEP INS
204 coronary heart disease 1 9.9 RETN INS ADIPOQ
205 carnitine palmitoyltransferase ii deficiency, infantile 9.9 PPARA HADHA
206 neurofibromatosis, type ii 9.8
207 autoimmune disease 9.8
208 adermatoglyphia 9.8
209 huntington disease 9.8
210 gilbert syndrome 9.8
211 cholestasis, intrahepatic, of pregnancy, 1 9.8
212 osteoporosis 9.8
213 papillomatosis, confluent and reticulated 9.8
214 polykaryocytosis inducer 9.8
215 triiodothyronine receptor auxiliary protein 9.8
216 citrullinemia, classic 9.8
217 enterocolitis 9.8
218 fanconi anemia, complementation group c 9.8
219 fanconi anemia, complementation group a 9.8
220 lymphoma, hodgkin, classic 9.8
221 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 9.8
222 microcephaly 1, primary, autosomal recessive 9.8
223 pancreatic cancer 9.8
224 short syndrome 9.8
225 thymoma, familial 9.8
226 chanarin-dorfman syndrome 9.8
227 wilson disease 9.8
228 ataxia and polyneuropathy, adult-onset 9.8
229 gallbladder disease 1 9.8
230 patent ductus venosus 9.8
231 autoimmune lymphoproliferative syndrome 9.8
232 xanthomatosis 9.8
233 chudley-mccullough syndrome 9.8
234 lymphoma, non-hodgkin, familial 9.8
235 late-onset retinal degeneration 9.8
236 carotid intimal medial thickness 2 9.8
237 malaria 9.8
238 isobutyryl-coa dehydrogenase deficiency 9.8
239 bone mineral density quantitative trait locus 8 9.8
240 diabetes mellitus, ketosis-prone 9.8
241 major affective disorder 8 9.8
242 major affective disorder 9 9.8
243 lung cancer susceptibility 3 9.8
244 leukemia, acute lymphoblastic 9.8
245 bone mineral density quantitative trait locus 15 9.8
246 aromatase deficiency 9.8
247 ectodermal dysplasia-syndactyly syndrome 2 9.8
248 hepatic lipase deficiency 9.8
249 muscle hypertrophy 9.8
250 glucocorticoid resistance, generalized 9.8
251 hyperlipoproteinemia, type iii 9.8
252 lipoprotein quantitative trait locus 9.8
253 peripheral vascular disease 9.8
254 angiosarcoma 9.8
255 hemophagocytic lymphohistiocytosis 9.8
256 metabolic acidosis 9.8
257 lymphoma 9.8
258 organic acidemia 9.8
259 crohn's colitis 9.8
260 pinta disease 9.8
261 aortic atherosclerosis 9.8
262 pulmonary edema 9.8
263 hepatorenal syndrome 9.8
264 allergic hypersensitivity disease 9.8
265 pulmonary alveolar proteinosis 9.8
266 primary biliary cirrhosis 9.8
267 marasmus 9.8
268 gout 9.8
269 biliary atresia 9.8
270 beriberi 9.8
271 thrombocytopenia due to platelet alloimmunization 9.8
272 ichthyosis 9.8
273 transient cerebral ischemia 9.8
274 hemangioma 9.8
275 severe acute respiratory syndrome 9.8
276 thymoma 9.8
277 bipolar disorder 9.8
278 myopathy 9.8
279 microsporidiosis 9.8
280 rhinitis 9.8
281 prostate disease 9.8
282 human immunodeficiency virus infectious disease 9.8
283 nephrolithiasis 9.8
284 congestive heart failure 9.8
285 bronchitis 9.8
286 severe combined immunodeficiency 9.8
287 adenoma 9.8
288 mitochondrial metabolism disease 9.8
289 end stage renal disease 9.8
290 periodontitis 9.8
291 osteoarthritis 9.8
292 retinal degeneration 9.8
293 ulcerative colitis 9.8
294 sideroblastic anemia 9.8
295 homocystinuria 9.8
296 diabetes insipidus 9.8
297 insr-related severe syndromic insulin resistance 9.8
298 medium-chain acyl-coenzyme a dehydrogenase deficiency 9.8
299 mitochondrial disorders 9.8
300 fasting hypoglycemia 9.8
301 glucagonoma 9.8
302 growth hormone deficiency 9.8
303 lipogranulomatosis 9.8
304 secondary adrenal insufficiency 9.8
305 aldosterone-producing adenoma 9.8
306 anoxia 9.8
307 headache 9.8
308 spinocerebellar degeneration 9.8
309 syncope 9.8
310 cerebrofacial arteriovenous metameric syndrome 9.8
311 primary hemophagocytic lymphohistiocytosis 9.8
312 acute sensory ataxic neuropathy 9.8
313 chronic intestinal failure 9.8
314 obesity due to melanocortin 4 receptor deficiency 9.8
315 other metabolic disease 9.8
316 fascioliasis 9.8 SLC17A5 INS GPT GGT1
317 skin tag 9.8 LEP INS
318 thyroid gland disease 9.7 LEP INS GPT
319 complete generalized lipodystrophy 9.7 LEP INS ADIPOQ
320 severe pre-eclampsia 9.7 LEP GPT ADIPOQ
321 arteriosclerosis 9.7 PPARA INS GPT ADIPOQ
322 protein-energy malnutrition 9.7 LEP GPT GGT1
323 sleep disorder 9.7 LEP INS ADIPOQ
324 idiopathic recurrent pericarditis 9.6 RETN LEP ADIPOQ
325 pericarditis 9.6 RETN LEP ADIPOQ
326 obesity-hypoventilation syndrome 9.6 RETN LEP ADIPOQ
327 uremia 9.6 RETN LEP INS
328 pre-eclampsia 9.5 LEP INS GPT ADIPOQ
329 hellp syndrome 9.4 SLC17A5 LEP HADHA GPT
330 adult syndrome 9.3 PPARA LEP INS ADIPOQ
331 anorexia nervosa 9.3 RETN LEP INS ADIPOQ
332 cerebrovascular disease 9.3 RETN LEP INS ADIPOQ
333 prader-willi syndrome 9.3 RETN LEP INS ADIPOQ
334 diabetes mellitus, type i 9.2 RETN LEP INS ADIPOQ
335 maturity-onset diabetes of the young 9.1 PPARA LEP INS GGT1 FABP1
336 abdominal obesity-metabolic syndrome quantitative trait locus 2 9.0 RETN PPARA LEP INS ADIPOQ
337 maturity-onset diabetes of the young, type 1 9.0 RETN PPARA LEP INS ADIPOQ
338 lysosomal storage disease 8.9 PPARA PNPLA3 LEP INS GPT ADIPOQ
339 glucose metabolism disease 8.7 RETN PPARA LEP INS GPT ADIPOQ
340 acquired metabolic disease 8.7 RETN PPARA LEP INS GPT ADIPOQ
341 myocardial infarction 8.7 RETN PPARA LEP INS GPT ADIPOQ
342 abdominal obesity-metabolic syndrome 1 8.5 RETN PPARA MTTP LEP INS ADIPOQ
343 inherited metabolic disorder 8.2 PPARA PNPLA3 MTTP LEP INS GPT

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

31 (showing 1, show less)
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 31 HP:0001397

Symptoms via clinical synopsis from OMIM:

56
Abdomen Liver:
fatty liver (hepatic steatosis), nonalcoholic

Clinical features from OMIM:

613282

MGI Mouse Phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

45 (showing 5, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 ADIPOQ FABP1 GGT1 HADHA INS LEP
2 adipose tissue MP:0005375 9.87 ADIPOQ INS LEP PNPLA3 PPARA PRMT7
3 liver/biliary system MP:0005370 9.85 ADIPOQ FABP1 HADHA INS LEP MTTP
4 muscle MP:0005369 9.43 ADIPOQ HADHA INS LEP PPARA PRMT7
5 renal/urinary system MP:0005367 9.1 ADIPOQ GGT1 HADHA INS LEP PPARA

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 445, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Ribavirin Approved Phase 4 36791-04-5 37542
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
Insulin aspart Approved Phase 4 116094-23-6 16132418
10
Insulin detemir Approved Phase 4 169148-63-4 5311023
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Glucagon Approved Phase 4 16941-32-5
13
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
14
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
17
Gliclazide Approved Phase 4 21187-98-4 3475
18
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
19
Zidovudine Approved Phase 4 30516-87-1 35370
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
22
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
23
Tamoxifen Approved Phase 4 10540-29-1 2733526
24
Ergotamine Approved Phase 4 113-15-5 8223
25
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
26
Nortriptyline Approved Phase 4 72-69-5 4543
27
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
32
Lenvatinib Approved, Investigational Phase 4 417716-92-8
33
Metformin Approved Phase 4 657-24-9 14219 4091
34
Dulaglutide Approved, Investigational Phase 4 923950-08-7
35
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
36
Alogliptin Approved Phase 4 850649-61-5 11450633
37
Empagliflozin Approved Phase 4 864070-44-0
38
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
39
Methyltestosterone Approved Phase 4 58-18-4 6010
40
Testosterone enanthate Approved Phase 4 315-37-7 9416
41
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
42
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
43
Zinc Approved, Investigational Phase 4 7440-66-6 32051
44
Insulin glargine Approved Phase 4 160337-95-1
45
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
46
Saxagliptin Approved Phase 4 361442-04-8 11243969
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
48
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
49
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
50
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
51
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
52 Tocotrienol Investigational Phase 4 6829-55-6
53 Ipragliflozin Investigational Phase 4 761423-87-4
54
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
55
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
56 Essential 303 forte Phase 4
57 Adrenergic alpha-Agonists Phase 4
58 Hypnotics and Sedatives Phase 4
59 Angiotensin-Converting Enzyme Inhibitors Phase 4
60 Anti-Infective Agents Phase 4
61 Immunologic Factors Phase 4
62 Interferon alpha-2 Phase 4
63 Olive Phase 4
64 Tocopherols Phase 4
65 Tocotrienols Phase 4
66 Antitubercular Agents Phase 4
67 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
68 Contraceptive Agents Phase 4
69 Rosuvastatin Calcium Phase 4 147098-20-2
70 Insulin degludec, insulin aspart drug combination Phase 4
71 Insulin, Long-Acting Phase 4
72 Silybin Phase 4
73 Lecithin Phase 4
74 Cytochrome P-450 Enzyme Inhibitors Phase 4
75 Integrase Inhibitors Phase 4
76 HIV Integrase Inhibitors Phase 4
77 Raltegravir Potassium Phase 4
78 Immunosuppressive Agents Phase 4
79 Salicylsalicylic acid Phase 4
80 Sodium salicylate Phase 4 54-21-7
81 calcium heparin Phase 4
82 Dihydroxycholecalciferols Phase 4
83 Hydroxycholecalciferols Phase 4
84 Lamivudine, zidovudine drug combination Phase 4
85 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
86 Estrogen Receptor Antagonists Phase 4
87 Estrogen Antagonists Phase 4
88 Estrogen Receptor Modulators Phase 4
89 Aromatase Inhibitors Phase 4
90 Triptorelin Pamoate Phase 4
91 Cytochrome P-450 CYP3A Inhibitors Phase 4
92 4-phenylbutyric acid Phase 4
93 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
94 Calcineurin Inhibitors Phase 4
95 Omega 3 Fatty Acid Phase 4
96 silymarin Phase 4
97 Iron Chelating Agents Phase 4
98 Anti-Arrhythmia Agents Phase 4
99 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isob... Phase 4
100 Estrogens Phase 4
101 Antineoplastic Agents, Hormonal Phase 4
102 Protein Kinase Inhibitors Phase 4
103 Anti-Retroviral Agents Phase 4
104 Anti-HIV Agents Phase 4
105 Gastrointestinal Agents Phase 4
106 Glucagon-Like Peptide 1 Phase 4
107 Sodium-Glucose Transporter 2 Inhibitors Phase 4
108 Pharmaceutical Solutions Phase 4
109 carnitine Phase 4
110 Reverse Transcriptase Inhibitors Phase 4
111 Testosterone 17 beta-cypionate Phase 4
112 Anabolic Agents Phase 4
113 Androgens Phase 4
114 Trace Elements Phase 4
115 Vitamins Phase 4
116 Nutrients Phase 4
117 Micronutrients Phase 4
118 Antioxidants Phase 4
119 Protective Agents Phase 4
120 Anti-Bacterial Agents Phase 4
121 Alpha-lipoic Acid Phase 4
122 Vitamin B Complex Phase 4
123 Thioctic Acid Phase 4
124 Folate Phase 4
125 Vitamin B9 Phase 4
126
Caffeine Approved Phase 2, Phase 3 58-08-2 2519
127
Losartan Approved Phase 3 114798-26-4 3961
128
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
129
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
130
Cysteamine Approved, Investigational Phase 2, Phase 3 60-23-1 6058
131
Vildagliptin Approved, Investigational Phase 3 274901-16-5 6918537
132
Lactulose Approved Phase 2, Phase 3 4618-18-2 11333
133
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
134
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
135
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
136
Lenograstim Approved, Investigational Phase 3 135968-09-1
137
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
138 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
139
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
140
chenodeoxycholic acid Approved Phase 3 474-25-9 10133
141
Atorvastatin Approved Phase 3 134523-00-5 60823
142
Maraviroc Approved, Investigational Phase 2, Phase 3 376348-65-1 3002977
143
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
144 Raspberry Approved Phase 2, Phase 3
145
Chromium Approved Phase 2, Phase 3 7440-47-3 27668
146
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
147
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898